Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells for creating new DNA when they multiply. Blocking the action of thymidylate synthase with a drug like Idetrexed may therefore stop cancers from growing by damaging DNA in cancer cells. Olaparib is a type of drug called a "PARP inhibitor". It prevents cells repairing DNA d

Trial Details

NCT ID
NCT06976892
Phase
PHASE1
Sponsor
Institute of Cancer Research, United Kingdom
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Dose Level 2 (starting dose)
  • Dose Level 1
  • Dose Level -1
  • Dose Level 3
  • Maximum Tolerated Dose
Locations (sample)
  • Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667
  • Sutton, London, United Kingdom|51.35,-0.2
  • Cardiff, Wales, United Kingdom|51.48,-3.18

Key Eligibility Criteria

  • Histologically or cytologically proven high grade serous ovarian cancer refractory to conventional treatment, or for which no conventional therapy …
  • Measurable (as defined by RECIST v1.1) or evaluable (based on tumour markers) disease.
  • Life expectancy of at least 12 weeks.
  • World Health Organisation (WHO) performance status of 0-1 (Appendix 1 of Protocol).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →